Piper Jaffray Starts Sutro Biopharma (STRO) at Overweight
Tweet
Share
E-mailGet Alerts STRO Hot Sheet
Price: $20.48 -3.89%
Rating Summary:
14 Buy, 1 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
14 Buy, 1 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Piper Jaffray analyst Edward Tenthoff initiates coverage on Sutro Biopharma (NASDAQ: STRO) with a Overweight rating and a price target of $23.00.
The analyst likes the revolutionary XpressCF platform, the potential upside from STRO-001 Phase 1 data in 2019, benefits from STRO-002 advancing into Clinic and the validating partnerships.
For an analyst ratings summary and ratings history on Sutro Biopharma click here. For more ratings news on Sutro Biopharma click here.
Shares of Sutro Biopharma closed at $14.53 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BofA Securities Resumes American Eagle Outfitters (AEO) at Underperform
- SoundThinking (SSTI) PT Lowered to $8 at Cantor Fitzgerald
- ICICI Securities Resumes Oberoi Realty Ltd (OBER:IN) at Buy (1)
Create E-mail Alert Related Categories
Analyst Comments, New CoverageRelated Entities
Piper Jaffray, Edward TenthoffSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
